CareSource Rxinnovations

INDIANA HEALTH COVERAGE PROGRAMS (IHCP)
ANTIVIRAL MONOCLONAL ANTIBODIES PRIOR AUTHORIZATION REQUEST FORM

CareSource Pharmacy Prior Authorization Form
P.O. Box 8738
Dayton, OH 45401-8738
Fax: (866) 930-0019

Today's Date ☐☐ / ☐☐ / ☐☐☐☐

Non-Urgent ☐ Urgent ☐

Note: This form must be completed by the prescribing provider.

*****All sections must be completed or the request will be returned.*****

Patient's CareSource # ☐☐☐☐☐☐☐☐☐☐☐☐	Date of Birth ☐☐ / ☐☐ / ☐☐☐☐
Patient's Name	Prescriber's Name
Prescriber's IN License # ☐☐☐☐☐☐☐☐	Specialty
Prescriber's NPI # ☐☐☐☐☐☐☐☐☐☐	Office Contact
Prescriber Fax ☐☐☐ - ☐☐☐ - ☐☐☐☐	Prescriber Phone ☐☐☐ - ☐☐☐ - ☐☐☐☐
Prescriber Address	Date(s) of Service: _____ Start Date: _____

Prior Authorization Requirements for Synagis (palivizumab):

1. Patient Information:
Actual Gestational Age: _____ weeks _____ days
Current Age (Must be < 24 months): _____ months
Current Weight: _____ ☐ kg ☐ lb

2. Prescription Information: ☐ Inject 15mg/kg IM once per month through March 31
☐ Other: _____

3. Palivizumab Prior Authorization Criteria Guidelines for a maximum of 5 doses (approval will be granted under any of the following circumstances)^:

If member is less than 12 months of age, select one of the following that is applicable:

☐ Member was born before 29 weeks, 0 days' gestation

☐ Member was born before 32 weeks, 0 days' gestation and has CLD necessitating more than 21 oxygen for at least the first 28 days of life
Please provide dates of oxygen supplementation/medication intervention:
_____

☐ Member has hemodynamically significant heart disease (e.g., acyanotic heart disease receiving medication to control CHF and will require cardiac surgical procedures, or those with moderate to severe pulmonary hypertension)
Please provide relevant diagnoses/medical intervention:
_____
_____

☐ Member has congenital airway abnormality or neuromuscular disease that impairs the ability to clear secretions

Please provide relevant diagnoses/medication intervention:
_____

☐ Member has cystic fibrosis with clinical evidence of CLD and/or nutritional compromise

If member is less than 24 months of age, select one of the following that is applicable:

☐ Member is or will be considered to be profoundly immunocompromised (must provide chart documentation and explicitly state how member is or will be considered to be profoundly immunocompromised during the RSV season), including members undergoing cardiac transplantation during current RSV season

Please explain:
_____

☐ Member was born before 32 weeks, 0 days' gestation and required at least 28 days of supplemental oxygen after birth and who continued to require supplemental oxygen, chronic systemic corticosteroid therapy, diuretic, or bronchodilator therapy within 6 months of the start of the second RSV season

Please provide dates of oxygen supplementation/medication intervention:
_____

☐ Member has cystic fibrosis with manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable) or weight-for-length <10th percentile

Please provide relevant diagnoses/medical intervention:
_____

4. Prescriber has submitted valid medical justification for the use of Synagis (palivizumab) over Beyfortus (nirsevimab)** ☐ YES ☐ NO

Medical justification:
_____
_____

***** For the 2023-2024 RSV season, lack of Beyfortus availability will be considered a medically justifiable reason for use of Synagis (palivizumab)***

5. Prescriber attests member has NOT received Beyfortus (nirsevimab) within the same RSV season:

☐ YES ☐ NO

Prescriber signature: _____ **Date:** _____

Note: *Prophylaxis will be given only until the infant/child reaches a maximum of 5 doses or the end of the RSV season, whichever comes first.*

^The Respiratory Syncytial Virus (RSV) season is defined as November 1 through March 31. The Office of Medicaid Policy & Planning may extend the season based on statewide virology data. Requests for additional doses beyond the initial 5 approved doses will require separate prior authorization.

IN-MED-P-2574107; Issued Date: 11/1/2023